Teduglutide for the treatment of short bowel syndrome: a double-edged sword?
- PMID: 37270286
- DOI: 10.1016/j.ajcnut.2023.04.009
Teduglutide for the treatment of short bowel syndrome: a double-edged sword?
Conflict of interest statement
Conflict of Interest SBO has provided consulting services to Takeda Pharmaceuticals. SAK has provided consulting services to Takeda Pharmaceuticals, Zealand Pharmaceuticals, and Alcresta Pharmaceuticals, and he is on the Abbott Nutrition Speakers’ Bureau. He has received research funding from Takeda Pharmaceuticals and VectivBio Pharmaceuticals.
Comment on
-
Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring.Am J Clin Nutr. 2023 Jun;117(6):1143-1151. doi: 10.1016/j.ajcnut.2023.02.015. Epub 2023 May 3. Am J Clin Nutr. 2023. PMID: 37270288
-
Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome.Am J Clin Nutr. 2023 Jun;117(6):1152-1163. doi: 10.1016/j.ajcnut.2023.02.019. Epub 2023 May 3. Am J Clin Nutr. 2023. PMID: 37270289
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
